PURPOSE: Circulating endothelial cells (CECs) and progenitor cells are currently evaluated as potential biomarkers of antiangiogenic therapy. CD146 is considered a panendothelial-specific marker, but its utility as a CEC marker in cancer patients remains unclear. PATIENTS AND METHODS: We analyzed the expression of CD146 on mononuclear blood cells, primary tissue endothelial cells, and malignant and normal tissues by flow cytometric and immunohistochemical analyses. Furthermore, we measured the circulation kinetics of CD146+ cells before, and then 3 and 12 days after vascular endothelial growth factor (VEGF) antibody blockade by bevacizumab infusion in rectal cancer patients enrolled in a phase I trial. RESULTS: In the peripheral blood of these cancer patients, over 90% of the CD146+ cells were CD45+ hematopoietic cells. CD146 expression was primarily detected on a subset of CD3+CD4+ lymphocytes, and was undetectable on CD34+CD133+CD45(dim) progenitor cells or CD31(bright)CD45- viable CECs. In contradistinction, CD146 was detectable in tissues on both cellular components of tumor vessel wall: CD31(bright)CD45- endothelial cells and alpha-SMA+ pericytes. Unlike viable CECs and progenitor cells, CD146+ cell concentration in the peripheral blood of cancer patients did not decrease during VEGF blockade. CONCLUSION: CD146 is fairly homogeneously expressed on vascular endothelium but not on viable CECs or progenitor cells. The vast majority of CD146+ blood cells are lymphocytes, and VEGF blockade by bevacizumab did not significantly change their number in rectal cancer patients. These results underscore the need for further characterization and identification of new markers for CEC subpopulations for their development as biomarkers of antiangiogenic therapy.
PURPOSE: Circulating endothelial cells (CECs) and progenitor cells are currently evaluated as potential biomarkers of antiangiogenic therapy. CD146 is considered a panendothelial-specific marker, but its utility as a CEC marker in cancerpatients remains unclear. PATIENTS AND METHODS: We analyzed the expression of CD146 on mononuclear blood cells, primary tissue endothelial cells, and malignant and normal tissues by flow cytometric and immunohistochemical analyses. Furthermore, we measured the circulation kinetics of CD146+ cells before, and then 3 and 12 days after vascular endothelial growth factor (VEGF) antibody blockade by bevacizumab infusion in rectal cancerpatients enrolled in a phase I trial. RESULTS: In the peripheral blood of these cancerpatients, over 90% of the CD146+ cells were CD45+ hematopoietic cells. CD146 expression was primarily detected on a subset of CD3+CD4+ lymphocytes, and was undetectable on CD34+CD133+CD45(dim) progenitor cells or CD31(bright)CD45- viable CECs. In contradistinction, CD146 was detectable in tissues on both cellular components of tumor vessel wall: CD31(bright)CD45- endothelial cells and alpha-SMA+ pericytes. Unlike viable CECs and progenitor cells, CD146+ cell concentration in the peripheral blood of cancerpatients did not decrease during VEGF blockade. CONCLUSION:CD146 is fairly homogeneously expressed on vascular endothelium but not on viable CECs or progenitor cells. The vast majority of CD146+ blood cells are lymphocytes, and VEGF blockade by bevacizumab did not significantly change their number in rectal cancerpatients. These results underscore the need for further characterization and identification of new markers for CEC subpopulations for their development as biomarkers of antiangiogenic therapy.
Authors: B St Croix; C Rago; V Velculescu; G Traverso; K E Romans; E Montgomery; A Lal; G J Riggins; C Lengauer; B Vogelstein; K W Kinzler Journal: Science Date: 2000-08-18 Impact factor: 47.728
Authors: S Monestiroli; P Mancuso; A Burlini; G Pruneri; C Dell'Agnola; A Gobbi; G Martinelli; F Bertolini Journal: Cancer Res Date: 2001-06-01 Impact factor: 12.701
Authors: Christopher G Willett; Yves Boucher; Dan G Duda; Emmanuelle di Tomaso; Lance L Munn; Ricky T Tong; Sergey V Kozin; Lucine Petit; Rakesh K Jain; Daniel C Chung; Dushyant V Sahani; Sanjeeva P Kalva; Kenneth S Cohen; David T Scadden; Alan J Fischman; Jeffrey W Clark; David P Ryan; Andrew X Zhu; Lawrence S Blaszkowsky; Paul C Shellito; Mari Mino-Kenudson; Gregory Y Lauwers Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Mohamed F Elshal; Sameena S Khan; Yoshiyuki Takahashi; Michael A Solomon; J Philip McCoy Journal: Blood Date: 2005-10-15 Impact factor: 22.113
Authors: Yuval Shaked; Francesco Bertolini; Shan Man; Michael S Rogers; Dave Cervi; Thomas Foutz; Kimberley Rawn; Daniel Voskas; Daniel J Dumont; Yaacov Ben-David; Jack Lawler; Jack Henkin; Jim Huber; Daniel J Hicklin; Robert J D'Amato; Robert S Kerbel Journal: Cancer Cell Date: 2005-01 Impact factor: 31.743
Authors: Paula Dore-Duffy; Afroza Mehedi; Xueqian Wang; Michael Bradley; Richard Trotter; Alexander Gow Journal: Microvasc Res Date: 2011-04-15 Impact factor: 3.514
Authors: Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain Journal: Cancer Cell Date: 2007-01 Impact factor: 31.743
Authors: Guangheng Li; Bo Zheng; Laura B Meszaros; Joseph B Vella; Arvydas Usas; Tomoyuki Matsumoto; Johnny Huard Journal: J Mol Cell Biol Date: 2011-07-04 Impact factor: 6.216
Authors: David A Reardon; Patrick Y Wen; Annick Desjardins; Tracy T Batchelor; James J Vredenburgh Journal: Expert Opin Biol Ther Date: 2008-04 Impact factor: 4.388
Authors: L Vroling; J S W Lind; R R de Haas; H M W Verheul; V W M van Hinsbergh; H J Broxterman; E F Smit Journal: Br J Cancer Date: 2009-12-15 Impact factor: 7.640